Nephrology最新文献

筛选
英文 中文
Augmented mannose-binding lectin levels in primary membranous nephropathy: A pilot study. 原发性膜性肾病患者甘露糖结合凝集素水平增高:一项试点研究。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 Epub Date: 2024-03-21 DOI: 10.1111/nep.14293
Deeksha Pal, Neeraj Inamdar, Prabhjot Kaur, Manphool Singhal, Anupam Lal, Ujjwal Gorsi, Ritambhra Nada, Harbir S Kohli, Vinod Kumar, Raja Ramachandran
{"title":"Augmented mannose-binding lectin levels in primary membranous nephropathy: A pilot study.","authors":"Deeksha Pal, Neeraj Inamdar, Prabhjot Kaur, Manphool Singhal, Anupam Lal, Ujjwal Gorsi, Ritambhra Nada, Harbir S Kohli, Vinod Kumar, Raja Ramachandran","doi":"10.1111/nep.14293","DOIUrl":"10.1111/nep.14293","url":null,"abstract":"<p><p>There is evidence to suggest that M-type phospholipase A2 (PLA2R) antibodies activate the mannose-binding lectin (MBL) cascade, resulting in glomerular damage and proteinuria in patients with primary membranous nephropathy (PMN). Furthermore, there are few reports indicating that aberrant MBL activation is associated with endothelial dysfunction and accelerated atherosclerosis. While PMN is a common cause of adult nephrotic syndrome, and patients are at increased risk of cardiovascular disease (CVD), there is a lack of research that explores the factors that contribute to this condition. This study aims to determine the MBL levels in PMN and their relation to the clinical activity and endothelial dysfunction in PMN. The MBL levels of 22 biopsy-confirmed PMN patients were assessed at baseline and after 6 months of immunosuppressive therapy. In order to evaluate endothelial dysfunction in PMN patients, flow-mediated vasodilation (FMD) was measured at baseline and after treatment. A total of 22 healthy controls were included in this study to measure MBL levels and FMD. A significant difference was observed between MBL levels in PMN patients and healthy controls (p < .01). MBL levels decreased significantly after immunosuppressive therapy (p = .04). The baseline MBL levels and FMD levels exhibited a strong correlation (Spearman correlation coefficient [ρ] = 0.51: p = .01). In conclusion, the study signals the activation of the MBL cascade and its association with endothelial dysfunction in PMN patients.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"617-621"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140175732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renal thrombotic microangiopathy is associated with poor renal survival in children with immunoglobulin A nephropathy. 肾血栓性微血管病与免疫球蛋白 A 肾病患儿肾脏存活率低有关。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 Epub Date: 2024-05-08 DOI: 10.1111/nep.14313
Meng Yang, Le Wang, Xiong-Fei Sun, Dong-Qi Yin
{"title":"Renal thrombotic microangiopathy is associated with poor renal survival in children with immunoglobulin A nephropathy.","authors":"Meng Yang, Le Wang, Xiong-Fei Sun, Dong-Qi Yin","doi":"10.1111/nep.14313","DOIUrl":"10.1111/nep.14313","url":null,"abstract":"<p><strong>Aim: </strong>The aim of this study was to examine the clinical and pathological characteristics as well as the prognosis of immunoglobulin A nephropathy (IgAN) accompanied by renal thrombotic microangiopathy (rTMA) in paediatric patients.</p><p><strong>Methods: </strong>After balancing epidemiological characteristics and pathological types between groups, 427 patients (rTMA group: 23, non-rTMA group: 46) were included. The clinical and pathological features, prognosis and clinical risk factors of the two groups were analysed.</p><p><strong>Results: </strong>IgAN-rTMA children showed more severe clinical and pathological manifestations. The findings from the logistic regression analysis indicated that hypercellularity 1 (E1) (HR: 0.805, 95% CI: 0.763 ~ 1.452, P = .016), endocapillary proliferation (HR: 1.214, 95% CI: 0.093 ~ 4.815, P = .025) and C3 staining (HR: 7.554, 95% CI: 2.563 ~ 15.729, P = .037) were the risk factors for rTMA in children with IgAN. The renal survival in rTMA group was lower than non-rTMA group (χ<sup>2</sup> = 18.467, P = .000). Cox regression analysis showed that E1 (HR: 7.441, 95% CI: 1.095 ~ 10.768, P = .037), C3 disposition (HR: 3.414, 95% CI: 0.834 ~ 11.578, P = .027) and rTMA (HR: 8.918, 95% CI: 1.032 ~ 16.754, P = .041) were identified as independent risk factors for the development of end-stage renal disease (ESRD).</p><p><strong>Conclusion: </strong>The presence of rTMA had a significant impact on the severity and prognosis of IgAN. And rTMA has been identified as an independent risk factor for the development of renal failure in children diagnosed with IgAN.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"579-587"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
17th International Symposium on IgA Nephropathy (IIgANN), 28-30 September, Tokyo. 第 17 届 IgA 肾病国际研讨会(IIgANN),9 月 28-30 日,东京。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 DOI: 10.1111/nep.14374
{"title":"17th International Symposium on IgA Nephropathy (IIgANN), 28-30 September, Tokyo.","authors":"","doi":"10.1111/nep.14374","DOIUrl":"https://doi.org/10.1111/nep.14374","url":null,"abstract":"","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"4"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current understanding and new insights in the treatment of IgA nephropathy. 目前对 IgA 肾病治疗的认识和新见解。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 Epub Date: 2024-07-03 DOI: 10.1111/nep.14340
Yuemiao Zhang, Hong Zhang
{"title":"Current understanding and new insights in the treatment of IgA nephropathy.","authors":"Yuemiao Zhang, Hong Zhang","doi":"10.1111/nep.14340","DOIUrl":"10.1111/nep.14340","url":null,"abstract":"<p><p>IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, and almost all patients are at risk of progression to end-stage kidney disease within their lifetime. The mechanisms responsible for the presentation and development of IgAN are required for the development of highly targeted therapies for this disease. In this review, we first demonstrate the current treatment strategy of IgAN recommended by the 2021 KDIGO guideline. Then, we update the new insights into disease pathogenesis based on the well acknowledged 'multiple-hit hypothesis' and provide the potential therapeutic targets involved in the upstream production of pathogenic IgA1 and the downstream complement activation. Finally, the recent large randomized controlled trials focusing on these novel targets have been summarized, among which Nefecon and Sparsentan have received approval and Telitacicept have been used off-label for IgAN. In the future, emerging treatment approaches for IgAN is likely to evolve, which will signify a shift in the management of the IgAN from traditional immunosuppressive approaches to an era of targeted treatment based on the understanding of the pathogenic mechanisms.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"75-79"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141492792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The pathogenesis of IgAN: Where is pathogenic IgA produced? IgAN 的发病机制:致病性 IgA 从何而来?
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1111/nep.14339
Heather N Reich, Yuko Makita
{"title":"The pathogenesis of IgAN: Where is pathogenic IgA produced?","authors":"Heather N Reich, Yuko Makita","doi":"10.1111/nep.14339","DOIUrl":"10.1111/nep.14339","url":null,"abstract":"","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"68-70"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141627171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Post-conference review of oral session 6 and short talk in the 17th international IgA nephropathy conference, Tokyo 2023. 东京 2023 年第 17 届国际 IgA 肾病会议口头报告 6 和简短发言的会后回顾。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 DOI: 10.1111/nep.14345
Suceena Alexander
{"title":"Post-conference review of oral session 6 and short talk in the 17th international IgA nephropathy conference, Tokyo 2023.","authors":"Suceena Alexander","doi":"10.1111/nep.14345","DOIUrl":"10.1111/nep.14345","url":null,"abstract":"<p><p>Oral session 6 titled 'Clinical Trial 1' and the short talk on 'Landscape of Clinical Trials in IgAN-What's beyond the Horizon?' took place on 30 September 2023 in the symposium venue. The short talk highlighted the increase in IgAN trials in the last decade and the challenges of global clinical trials from the site investigator perspective. The talk also underlined the importance of relooking and repurposing already available and approved therapeutics. There were six oral sessions that focussed mainly on the interim results of ongoing clinical trials as well as early phase results with new investigational agents.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"63-64"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7616661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mucosa targeting therapy for IgA nephropathy: Upper respiratory mucosa. IgA 肾病的粘膜靶向疗法:上呼吸道粘膜
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 DOI: 10.1111/nep.14348
Takashi Yokoo
{"title":"Mucosa targeting therapy for IgA nephropathy: Upper respiratory mucosa.","authors":"Takashi Yokoo","doi":"10.1111/nep.14348","DOIUrl":"10.1111/nep.14348","url":null,"abstract":"","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"37-38"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Closing remarks from the IIGANN2023 Tokyo symposium-40 years of study progress in IgA nephropathy. IIGANN2023 东京研讨会闭幕词--IgA 肾病研究进展 40 年。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 DOI: 10.1111/nep.14344
Renato C Monteiro
{"title":"Closing remarks from the IIGANN2023 Tokyo symposium-40 years of study progress in IgA nephropathy.","authors":"Renato C Monteiro","doi":"10.1111/nep.14344","DOIUrl":"https://doi.org/10.1111/nep.14344","url":null,"abstract":"","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"80-83"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
My lifetime in IgA nephropathy: An unexpected journey. 我与 IgA 肾病的一生:意想不到的旅程
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 DOI: 10.1111/nep.14341
Bruce A Julian
{"title":"My lifetime in IgA nephropathy: An unexpected journey.","authors":"Bruce A Julian","doi":"10.1111/nep.14341","DOIUrl":"10.1111/nep.14341","url":null,"abstract":"","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"55-59"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11441621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The epidemiology of IgA nephropathy: East versus West. IgA 肾病的流行病学:东方与西方。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 DOI: 10.1111/nep.14349
Sean J Barbour
{"title":"The epidemiology of IgA nephropathy: East versus West.","authors":"Sean J Barbour","doi":"10.1111/nep.14349","DOIUrl":"10.1111/nep.14349","url":null,"abstract":"","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"65-67"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信